Azacitidine - Allergan

Drug Profile

Azacitidine - Allergan

Latest Information Update: 17 May 2016

Price : $50

At a glance

  • Originator Allergan
  • Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Myelodysplastic syndromes

Most Recent Events

  • 17 May 2016 Chemical structure information added
  • 29 Apr 2016 Registered for Myelodysplastic syndromes in USA (IV)
  • 29 Apr 2016 Registered for Myelodysplastic syndromes in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top